HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

7- n- butyl- 6- (4'- hydroxyphenyl)- 5H- pyrrolo(2,3b)pyrazine

structure in first source

Also Known As:

aloisine A

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrroles: 369
      - 7-n-butyl-6-(4'-hydroxyphenyl)-5H-pyrrolo(2,3b)pyrazine: 3
  - Pyrazines: 150
    - 7-n-butyl-6-(4'-hydroxyphenyl)-5H-pyrrolo(2,3b)pyrazine: 3

Experts

1.	Huang, Qi: 1 article (03/2013)
2.	Kang, Hong: 1 article (03/2013)
3.	Tian, Chuan: 1 article (03/2013)
4.	Wu, Qiong: 1 article (03/2013)
5.	Zhu, Ruixin: 1 article (03/2013)
6.	Renaud, Martin: 1 article (02/2011)
7.	Rivest, Patricia: 1 article (02/2011)
8.	Sanderson, J Thomas: 1 article (02/2011)
9.	Ceballos-Picot, Irène: 1 article (01/2003)
10.	Endicott, Jane: 1 article (01/2003)

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease) 01/16/2003 - "A selectivity study performed on 26 kinases shows that aloisine A is highly selective for CDK1/cyclin B, CDK2/cyclin A-E, CDK5/p25, and GSK-3 alpha/beta; the two latter enzymes have been implicated in Alzheimer's disease. "
2.	Neurodegenerative Diseases (Neurodegenerative Disease) 03/01/2013 - "Competitive inhibition of the ATP-binding pocket of CDK5 is involved in fighting with neurodegenerative diseases, diabetes, tumors, inflammations etc. To better design ATP-binding competitive inhibitors, the binding mechanism of three important inhibitors of kinases, (R)-roscovitine (RRC), aloisine-A (ALH) and indirubin-3'-oxime (IXM), together with their receptor CDK5, were studied by molecular dynamics simulations. "
3.	Prostatic Neoplasms (Prostate Cancer) 02/01/2011 - "We evaluated the effects of aloisine A, alsterpaullone, aminopurvalanol, indirubin-3'-oxime, 6-Br-indirubin-3'-oxime, kenpaullone, olomoucine and roscovitine on cell proliferation, prostate-specific antigen (PSA) expression, androgen receptor (AR) activation, and GSK-3β and β-catenin expression in androgen-dependent LNCaP human prostate cancer cells. "
4.	Neoplasms (Cancer) 03/01/2013 - "Competitive inhibition of the ATP-binding pocket of CDK5 is involved in fighting with neurodegenerative diseases, diabetes, tumors, inflammations etc. To better design ATP-binding competitive inhibitors, the binding mechanism of three important inhibitors of kinases, (R)-roscovitine (RRC), aloisine-A (ALH) and indirubin-3'-oxime (IXM), together with their receptor CDK5, were studied by molecular dynamics simulations. "
5.	Inflammation (Inflammations) 03/01/2013 - "Competitive inhibition of the ATP-binding pocket of CDK5 is involved in fighting with neurodegenerative diseases, diabetes, tumors, inflammations etc. To better design ATP-binding competitive inhibitors, the binding mechanism of three important inhibitors of kinases, (R)-roscovitine (RRC), aloisine-A (ALH) and indirubin-3'-oxime (IXM), together with their receptor CDK5, were studied by molecular dynamics simulations. "

Related Drugs and Biologics

1.	Phosphotransferases (Kinase)
2.	Glycogen Synthase Kinase 3
3.	Cyclin B
4.	Cyclin A
5.	Enzymes
6.	Roscovitine
7.	Catenins
8.	Prostate-Specific Antigen (Semenogelase)
9.	Androgen Receptors (Androgen Receptor)
10.	Androgens